XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.

XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
A
A

Abbott

Haberler

Reuters - 1 hafta önce

Abbott India gains on upbeat Q1 results

BUZZ-Abbott India gains on upbeat Q1 results ** Shares of Abbott India ABOT.NS climb ~4% to 29,139.30 rupees, their highest since February ** Drugmaker reports 13% Y/Y rise in Q1 consol net profit ; 5.3% Y/Y rev growth ** Stock top pct gainer in pharma index .NIPHARM , which is up ~1% ** Trading volume 2.4x the 30-day moving average ** ABOT among 1
A
Reuters - 1 hafta önce

India economic, corporate events on August 8

DIARY- India economic, corporate events on August 8 BENGALURU, Aug 8 (Reuters) - Diary of India economic, corporate events on August 8. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INREPO=ECI 8 Aug 2024 10:00 Repo Rate 8 Aug 6.50% 6.50% INRREP=ECI 8 Aug 2024 10:00 Reverse Repo Rate 8 A
A
A
A
B
B
Reuters - 1 hafta önce

U.S. STOCKS Abbott Laboratories, Medtronic, Axon

BUZZ-U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes advanced on Wednesday, aided by a dovish turn by Japan's top policymaker after a surprise interest rate hike last week which partly sparked heavy volatility in global markets.
A
A
C
F
I
T
U
U
L
Reuters - 1 hafta önce

Some diabetes device makers fall after Abbott, Medtronic glucose monitoring partnership

BUZZ-Some diabetes device makers fall after Abbott, Medtronic glucose monitoring partnership ** Shares of Tandem diabetes care TNDM.O fall ~9.9% to $39.17 ** Medical device makers Abbott Laboratories ABT.N and Medtronic MDT.N have entered into a partnership to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin del
A
C
Reuters - 1 hafta önce

Abbott, Medtronic rise on glucose monitoring partnership

BUZZ-Abbott, Medtronic rise on glucose monitoring partnership Updates ** Shares of medical device makers Abbott Laboratories ABT.N rise 1.7% to $111.36 and Medtronic MDT.N r ise 1.8% to $82 .24 ** ABT says it has entered into a global partnership with MDT to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin deliv
A
Reuters - 1 hafta önce

Abbott, Medtronic rise on glucose monitoring partnership

BUZZ-Abbott, Medtronic rise on glucose monitoring partnership ** Shares of medical device makers Abbott Laboratories ABT.N and Medtronic MDT.N rise 2.3% to $112.03 and $82.64, respectively ** ABT says it has entered into a global partnership with MDT to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin delivery s
A
Reuters - 1 hafta önce

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes BENGALURU, Aug 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes. The company, which makes the popular antacid medicine Digene, said its profit rose to 3.28 billion rupees ($39.1 million) for the quarter ended June 30, a 13% rise from last year.
A
G
P
Reuters - 1 hafta önce

India economic, corporate events on August 7

DIARY- India economic, corporate events on August 7 BENGALURU, Aug 7 (Reuters) - Diary of India economic, corporate events on August 7. ECONOMIC, CORPORATE .BSE500 EVENTS: Key Speaker Local Time Location India commerce minister 0930 BIMSTEC Business Summit, New Delhi India financial services secretary 1000 Industry body FICCI event, New Delhi RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INM3MS=ECI 7 Aug 2024 17:00 M3 Money Supply 26 Jul, w/e 10.7% Start Date Start Tim
A
B
C
Reuters - 2 hafta önce

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand BENGALURU, Aug 2 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupe
A
G
P
Reuters - 2 hafta önce

Becton Dickinson tops profit estimates on demand for drug-delivery devices

Becton Dickinson tops profit estimates on demand for drug-delivery devices Aug 1 (Reuters) - Becton Dickinson BDX.N reported a better-than-expected third -quarter profit on Thursday , helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, catch up on surgeries that were put on hold during the pandemic.
A
B
Reuters - 2 hafta önce

S&P 500 barely rises as investors await key results, jobs data, Fed meeting

US STOCKS-S&P 500 barely rises as investors await key results, jobs data, Fed meeting Tesla rallies after Morgan Stanley adds stock to 'top pick' list McDonald's rises on strong up-take of $5-meal deal Crypto stocks reverse earlier gains Indexes: Dow off 0.12%, S&P up 0.08%, Nasdaq up 0.07% Updates with closing prices, data By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The S&P 500 c losed barely higher after Monday's choppy trading session as investors h eld their breath ahead of a raft
A
A
A
M
T
U
U
U
Reuters - 2 hafta önce

S&P 500 rises slightly ahead of key results, data, Fed meeting

US STOCKS-S&P 500 rises slightly ahead of key results, data, Fed meeting Adds preliminary closing prices at 4 p.m ET/ 2000 GMT By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The S&P 500 c losed up slightly after Monday's choppy trading as investors anxiously awaited a raft of technology company earnings, a Federal Reserve policy decision on interest-rate cuts and key US labor data, all due this week.
A
A
A
M
T
U
U
U
Reuters - 2 hafta önce

U.S. indexes up in choppy session ahead of key results and data, Fed meeting

US STOCKS-U.S. indexes up in choppy session ahead of key results and data, Fed meeting Tesla up after Morgan Stanley adds stock to 'top pick' list McDonald's jumps on $5-meal deal beat Crypto stocks fall, Abbott drops after formula verdict Indexes: Dow off 0.02%, S&P up 0.15%, Nasdaq up 0.15% Updated prices at 2:29 p.m ET/ 1829 GMT By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The Nasdaq and S&P 500 edged higher on Monday in choppy trading as investors anxiously awaited a raft of techno
A
A
A
M
T
U
U
U
Reuters - 2 hafta önce

U.S. STOCKS Bank of Marin Bancorp, ON Semiconductor, Walt Disney

BUZZ-U.S. STOCKS ON THE MOVE-Bank of Marin Bancorp, ON Semiconductor, Walt Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 rose in choppy, range-bound trading on Monday as investors looked forward to a raft of upcoming triggers such as Big Tech earnings, a Federal Reserve policy decision on interest-rate cuts and key labor data.
A
A
A
C
N
T
O
U
U
Reuters - 2 hafta önce

U.S. STOCKS Ventyx Biosciences, McDonald's, Pinterest

BUZZ-U.S. STOCKS ON THE MOVE-Ventyx Biosciences, McDonald's, Pinterest Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 rose on Monday, buoyed by megacap stocks as investors awaited Big Tech results, a Federal Reserve policy decision and crucial labor numbers this week.
A
A
A
N
P
T
O
U
U
Reuters - 2 hafta önce

London's FTSE 100 nudges higher on rate optimism

UPDATE 1-London's FTSE 100 nudges higher on rate optimism For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100 up 0.1%, FTSE 250 off 0.5% Pharma shares lead gains US, UK rate decisions in focus Updated at 1550 GMT By Purvi Agarwal and Shubham Batra July 29 (Reuters) - Britain's FTSE 100 closed slightly higher on Monday, boosted by real estate shares on optimism around interest rate cuts in the U.S.
A
A
A
M
U
Reuters - 2 hafta önce

U.S. STOCKS Tesla, Guardant Health, Abbott Laboratories

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Guardant Health, Abbott Laboratories Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were poised for a strong opening on Monday, as investors geared up for a Federal Reserve interest-rate decision, along with Big Tech earnings and crucial labor numbers after the recent equity sell-off.
A
A
N
P
T
O
U
Reuters - 2 hafta önce

Futures rise as Fed verdict, Big Tech results expected this week

US STOCKS-Futures rise as Fed verdict, Big Tech results expected this week For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures up: Dow 0.27%, S&P 500 0.28%, Nasdaq 0.44% July 29 (Reuters) - U.S. index futures climbed on Monday after the recent market rout, as investors girded up for a busy week marked by a Federal Reserve interest-rate decision, eagerly awaited tech earnings and crucial labor data.
A
A
A
G
M
T
U
U
U
Reuters - 2 hafta önce

Abbott shares slide after trial verdict, weigh on rival Reckitt Benckiser

UPDATE 2-Abbott shares slide after trial verdict, weigh on rival Reckitt Benckiser Adds Reckitt statement in paragraph 10 July 29 (Reuters) - Abbott Laboratories' ABT.N shares fell nearly 7% premarket, while British peer Reckitt Benckiser RKT.L slumped 9% on Monday, after the U.S. healthcare firm was ordered to pay $495 million in damages related to its formula for premature infants.
A
Reuters - 2 hafta önce

Abbott slides after co to pay $495 mln in premature infant formula trial

BUZZ-Abbott slides after co to pay $495 mln in premature infant formula trial ** Shares of Abbott ABT.N down 7.1% to $97.76 premarket ** A jury found Abbott's specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering co to pay $495 mln in damages ** The verdict state court comes in the first tr
A

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.